Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc.

SLNO·NASDAQ

$53.01

+0.038%
HealthcareBiotechnology

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

At a Glance

Live Snapshot
Market Cap$2.76B
EPS0.4100
P/E Ratio117.86
Earnings Date08/05/2026

slno

Operating Expenses

Last Annual Value

172.75M

3-Year CAGR

92%

5-Year CAGR

42%

10-Year CAGR

30%

Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. Competitors Analysis of Operating Expenses

SLNO · NASDAQ
CompanyOperating Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
172.75M
61.0%40.5%29.0% 
1.10B
4.7%8.9%16.0%
466.13M
24.8%25.4%11.2%
CELC logo
Celcuity Inc.
NASDAQ:CELC
172.19M
37.5%43.4%48.4%
326.06M
97.9%14.3%N/A
393.34M
57.4%47.8%39.7%
284.18M
45.1%N/AN/A
443.21M
21.3%18.4%N/A
Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. Fair Value Envelope

SLNO · NASDAQ

Our analysis suggests that SLNO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $53.01, this represents a potential HIDDEN relative to our calculated worth for Soleno Therapeutics, Inc..

Intrinsic Value
Current Price: $53.01